UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 8,690 Shares of Orthofix Medical Inc. (NASDAQ:OFIX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in Orthofix Medical Inc. (NASDAQ:OFIX) by 12.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 62,599 shares of the medical device company’s stock after selling 8,690 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Orthofix Medical were worth $978,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Armistice Capital LLC grew its position in shares of Orthofix Medical by 1.4% in the second quarter. Armistice Capital LLC now owns 3,750,000 shares of the medical device company’s stock valued at $49,725,000 after purchasing an additional 50,000 shares during the last quarter. Rubric Capital Management LP boosted its stake in Orthofix Medical by 0.8% in the 2nd quarter. Rubric Capital Management LP now owns 3,694,946 shares of the medical device company’s stock valued at $48,995,000 after purchasing an additional 29,946 shares during the period. Engine Capital Management LP boosted its stake in Orthofix Medical by 11.0% in the 2nd quarter. Engine Capital Management LP now owns 3,368,665 shares of the medical device company’s stock valued at $44,668,000 after purchasing an additional 333,364 shares during the period. Paradigm Capital Management Inc. NY grew its holdings in Orthofix Medical by 31.3% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 2,556,100 shares of the medical device company’s stock valued at $33,894,000 after buying an additional 609,137 shares in the last quarter. Finally, AYAL Capital Advisors Ltd increased its position in Orthofix Medical by 10.2% during the 2nd quarter. AYAL Capital Advisors Ltd now owns 686,794 shares of the medical device company’s stock worth $9,107,000 after buying an additional 63,697 shares during the period. 89.76% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently issued reports on OFIX. Stifel Nicolaus raised shares of Orthofix Medical from a “hold” rating to a “buy” rating and boosted their target price for the company from $18.00 to $24.00 in a research report on Friday, November 8th. Roth Mkm reiterated a “buy” rating and issued a $22.00 price objective (up previously from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Orthofix Medical has an average rating of “Moderate Buy” and an average target price of $23.00.

Orthofix Medical Trading Down 2.2 %

Shares of NASDAQ:OFIX opened at $17.53 on Thursday. The business’s 50 day simple moving average is $17.71 and its 200 day simple moving average is $16.15. Orthofix Medical Inc. has a 1 year low of $12.08 and a 1 year high of $20.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11. The company has a market capitalization of $669.89 million, a P/E ratio of -5.60 and a beta of 1.09.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.